From: Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
Parameter | baseline | day 2 | day 14 | (female) | ||
---|---|---|---|---|---|---|
vehicle | Nz-800CW | vehicle | Nz-800CW | |||
mean ± sd | mean ± sd | mean ± sd | unit | |||
GR | 7.0 ± NA | 4.6 ± 1.4 | 4.1 ± 2.3 | 2.8 ± 0.3 | 3.1 ± 1.6 | % |
Hct | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.0 | 0.5 ± 0.1 | 0.5 ± 0.0 | L/L |
Hgb | 160 ± 22 | 138 ± 22 | 140 ± 12 | 156 ± 19 | 161 ± 13 | g/L |
LY | 77.8 ± NA | 79.8 ± 4.3 | 82.9 ± 2.3 | 85.2 ± 1.2 | 83.6 ± 6.9 | % |
MCH | 18.9 ± 0.3 | 18.6 ± 1.2 | 17.2 ± 0.3 | 19.0 ± 0.5 | 19.2 ± 0.2 | gp |
MCHC | 322 ± 1.3 | 320 ± 1.7 | 321 ± 0.6 | 321 ± 1.2 | 322 ± 0.5 | g/L |
MCV | 58.7 ± 1.0 | 58.0 ± 3.5 | 53.7 ± 1.0 | 59.1 ± 1.6 | 59.5 ± 0.6 | fL |
MO | 15.2 ± NA | 15.5 ± 2.9 | 13.0 ± 1.2 | 12.1 ± 1.2 | 13.4 ± 5.3 | % |
Plt | 703 ± 173 | 602 ± 160 | 453 ± 318 | 630 ± 217 | 711 ± 137 | ×10^9/L |
RBC | 9.0 ± 0.4 | 8.2 ± 0.5 | 7.5 ± 0.8 | 8.8 ± 0.2 | 8.8 ± 0.6 | ×10^12/L |
RDW | 19.3 ± 7.1 | 19.1 ± 1.2 | 20.8 ± 0.9 | 15.7 ± 0.7 | 15.5 ± 0.3 | % |
WBC | 0.9 ± 0.4 | 1.1 ± 0.3 | 2.2 ± 0.5 | 1.9 ± 1.5 | 1.0 ± 0.4 | × 10^9/L |